Exactech (NSDQ:EXAC) revealed results from 10 new studies that the company said highlighted the benefit of its knee and shoulder implants.

Two knee-related studies focused on results from Exactech’s Truliant total knee arthroplasty cases and postoperative outcomes with the Optetrak Logic knee system for both men and women. Two further studies centered around the Equinoxe for shoulder stability.

One-year clinical outcomes from the first Truliant primary cases resulted in satisfaction rates that reached 9.2 out of 10, along with higher scores in patient-reported outcomes and range of motion post-surgery. The company announced the successful first surgeries involving Truliant in June. At the time, Exactech said the implant was in a limited launch with full U.S. market availability expected in early 2020.

A separate study of 458 total knee arthroplasty cases showed that the Optetrak Logic plants provided “equivalent and significant” postoperative improvement for man and women, both in outcomes and range of motion, according to a news release.

A study on machine learning programs’ accuracy in outcome prediction and intraoperative load sensors’ use in assessing shoulder stability revealed accuracy of approximately 89.5% with the Equinoxe. Another study using intraoperative load sensors in reverse total shoulder arthroplasty found sensors accurately quantified joint load and helped assess shoulder stability.

“The results of the studies presented demonstrate great progress in the Exactech knee and shoulder lines,” The Medical University of South Carolina’s Dr. Richard Friedman said in the release. “Throughout the development of the Truliant and Equinoxe systems, our teams have maintained dedication to putting patients first and developing the joint replacement solutions surgeons need. It’s a privilege to have been able to share some of these key results at the congress.”